Article written by Maria Dalby. Interview by Hannah Chatfield. Another study with significant practice implications is the COLUMBA study, presented by Professor Maria-Victoria Mateos (University Hospital of Salamanca, Spain). This… read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Oral selective BCL-2 inhibitor venetoclax has demonstrated encouraging clinical efficacy against MM. As monotherapy, venetoclax has shown to be… read more.
Faouzi Djebbari (Oxford) also gives his thoughts on the unmet needs of the newly diagnosed MM patient who is ineligble for stem cell transplantation.
In addition to clinical segmentation of MM patients as young or elderly and fit or frail, genetic factors convey important prognostic information and should be taken into account… read more.
Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd)… read more.
The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.
When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.
The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.
One in four people leave their job within a year of returning to work after having a heart attack, according to a study from Denmark in the Journal… read more.
Lactation duration appears to be inversely related to development of type 2 diabetes, researchers reported in the March 2018 issue of JAMA Internal Medicine.
As a community IBD professionals are well aware of the need to raise the bar in terms of delivering quality care that maintains tight disease control and anticipates… read more.
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
